(Q34232543)

31 July 2017

1 reference

title

The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity (English)

1 reference

31 July 2017

Wang RF

1

1 reference

31 July 2017

publication date

1 May 2001

1 reference

31 July 2017

1 reference

31 July 2017

volume

22

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

269-276

1 reference

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Human tumor antigens for cancer vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The dendritic cell and human cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CD4 T cells and their role in antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The role of CD4+ T cell responses in antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CD4+ T-cell subsets in autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Therapeutic vaccination against chronic viral infection: the importance of cooperation between CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Crossregulation Between Th1 and Th2 Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Immunotherapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Clinical trials of antibody therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A unique tumor antigen produced by a single amino acid substitution

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Invariant chain structure and MHC class II function

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of HLA-class-II-restricted epitopes of autoantigens in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

1 reference

7 January 2021

Cancer therapy using a self-replicating RNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

The makings of a tumor rejection antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

Costimulatory wars: the tumor menace

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4906%2801%2901896-8

7 January 2021

10.1016/S1471-4906(01)01896-8

Identifiers

DOI

1 reference

31 July 2017

1 reference